ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator
Cercetare și inovare
From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit May 15 2026 ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression. In an exploratory PK study in healthy volunteers (n = 13), EMRX-101 (4 mg) delivered approximately
astăzi